Loading...
Market
First major pharma company to adopt UCL's AI blood test tech by end of 2024?
5
Resolution / Starting Odds
Pfizer • 25%
Roche • 25%
Novartis • 25%
Other • 25%
Official announcements or press releases from pharmaceutical companies
Story
UCL's AI-Powered Blood Test Predicts Parkinson's Seven Years Before Symptoms Using Protein Biomarkers
Jun 18, 2024, 03:52 PM
Researchers have developed an AI-powered blood test that can predict Parkinson's disease up to seven years before symptoms appear. The test, created by scientists at University College London (UCL), identifies a biological signature of the disease by analyzing a panel of eight protein biomarkers, including alpha-synuclein. This breakthrough could revolutionize early diagnosis and treatment of Parkinson's, a degenerative condition caused by the death of nerve cells in the brain that controls movement. The findings, published in Nature Communications, offer hope for better management of the disease, which affects approximately 153,000 people in the UK.
View original story
Similar markets
Yes • 50%
No • 50%
Pfizer • 25%
Roche • 25%
Eli Lilly • 25%
Other • 25%
Pfizer • 25%
Johnson & Johnson • 25%
Roche • 25%
Other • 25%
Google DeepMind • 25%
Microsoft • 25%
IBM • 25%
Other • 25%
Pfizer • 25%
Merck • 25%
Johnson & Johnson • 25%
Other • 25%
Mayo Clinic • 25%
Cleveland Clinic • 25%
Kaiser Permanente • 25%
Other • 25%
Pfizer • 25%
Johnson & Johnson • 25%
Novartis • 25%
Other • 25%
Pfizer • 25%
Moderna • 25%
Johnson & Johnson • 25%
Other • 25%
Yes • 50%
No • 50%
Insilico Medicine • 25%
Amgen • 25%
Nested Therapeutics • 25%
Other • 25%
Yes • 50%
No • 50%
Pfizer • 25%
Roche • 25%
Novartis • 25%
Other • 25%